Skip to main content
Fig. 3 | BMC Pulmonary Medicine

Fig. 3

From: Use of leflunomide in patients with chronic hypersensitivity pneumonitis

Fig. 3

Trajectory of pulmonary function before and after LEF treatment in patients with fibrosis ≤20%. a FVC decline of 3.76 ± 3.18% (SEM) predicted/year was reversed to an increase of 4.52 ± 1.67% predicted/year with treatment. FVC% predicted increased significantly at 12 months (mean increase 8.3% predicted; 95% CI, 3.6 to 13.0%; p < 0.001). b The DLCO slope did not change significantly, from a DLCO of − 4.79 ± 2.57% (SEM) predicted/year to − 0.036 ± 1.31% predicted/year (p = 0.140), but DLCO% predicted increased significantly at 12 months (mean increase 4.8%predicted; 95% CI, 1.1 to 8.5%; p = 0.011)

Back to article page